ClinicalTrials.gg
WithdrawnNCT02442674Updated Jul 31, 2017

A Trial of Tolvaptan in Children and Adolescent Subjects With Euvolemic and Hypervolemic Hyponatremia

A Phase 3 interventional study of Tolvaptan and Placebo in Hyponatremia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Withdrawn. Open to participants aged 4 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-07-31.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Trial withdrawn due to inability to meet the trial objectives (Pilot).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
4 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing tolvaptan in Hyponatremia — none open to participants now, none under way, none of them phase 3. Tolvaptan · Hyponatremia.

Enrollment
20th of 20
0 · median 55
Started
2015
with 2 others
Phase 3
9 of 20
none open now
Registered
16th of 20
by date
Lead sponsor
8 of 20
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 20 studies testing tolvaptan in Hyponatremia, this one is the 20th largest by enrollment, is one of 3 that started in 2015, is one of 9 in phase 3, and was the 16th registered.

Hyponatremia

164 studies on the registry are indexed under Hyponatremia; 16 are open to participants now.

Browse Hyponatremia studies →

Open to participants now

None of the 20 studies testing tolvaptan in Hyponatremia is open now. The open studies under Hyponatremia, anywhere →

About tolvaptan

Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Hyponatremia studies recruiting now, 13 (93%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 4 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing tolvaptan in Hyponatremia as a file.
02

Study summary

The purpose of this trial is to demonstrate that tolvaptan effectively and safely increases and maintains serum sodium concentrations in children and adolescent subjects with euvolemic or hypervolemic hyponatremia.

Read the detailed description

The purpose of the study is to also assess tolvaptan's pharmacokinetics (PK) and its effect on fluid balance in children and adolescent subjects with euvolemic or hypervolemic hyponatremia. Subjects who are diagnosed with euvolemic or hypervolemic hyponatremia (serum sodium \< 130 mEq/L [mmol/L]) that persists despite initial standard background therapy (eg, including fluid restriction) are eligible to be screened for participation in this trial. Subjects who demonstrate prior resistance to vasopressin antagonist therapy will be excluded. All potential subjects must be deemed by the investigator as likely to benefit from a therapy that raises serum sodium levels.

Subjects will be required to be in a hospital setting during initiation or titration of tolvaptan. Overall, in this trial, subjects will undergo treatment with tolvaptan or placebo for 30 (+2) days and a post-last dose follow-up phase of 14 days.

03

Conditions studied

  • Hyponatremia

Keywords

  • Hyponatremia
  • Euvolemic
  • Hypervolemic
  • Serum sodium
  • Dilutional hyponatremia
  • Electrolyte abnormality
  • Electrolyte imbalance
  • Metabolic disease
  • Water-Electrolyte Imbalance
04

Who can participate

Ages eligible
4 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female subjects ≥ 4 years of age (or per local Health Authority age restriction) to \< 18 years old and ≥ 10kg
  2. Subjects hospitalized with euvolemic or hypervolemic hyponatremia resistant to initial standard background therapy (including fluid restriction and excluding a vasopressin antagonist) and who are deemed by the investigator as likely to benefit from a therapy that raises serum sodium levels
  3. Persistent euvolemic or hypervolemic hyponatremia defined as being documented as present for at least 48 hours, evidenced by at least 2 serum sodium assessments \< 130 mmol/L drawn at least 12 hours apart (these values can be documented using historical values previously obtained per standard of care); a third (STAT) serum sodium assessment \< 130 mmol/L, which will serve as the baseline value for efficacy endpoints, is to be obtained within 2-4 hours prior to the final trial qualification and the first dose of IMP
  4. Ability to swallow tablets
  5. Ability to maintain adequate fluid intake whether orally or via IV support with adequate monitoring
  6. Ability to comply with all requirements of the trial
  7. Trial-specific written /assent obtained from a parent/legal guardian or legally acceptable representative, as applicable per age of subject or local laws, prior to the initiation of any protocol required procedures. In addition, the subject as required by local laws must provide informed assent at Screening and must be able to understand that he or she can withdraw from the trial at any time.

    All informed consent/assent procedures must be in accordance with the trial center's IRB/IEC and local regulatory requirements

  8. Ability to commit to remain fully abstinent (periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] or withdrawal are not acceptable methods of ) or practice double-barrier birth control during the trial and for 30 days following the last dose of IMP for sexually active females of

Exclusion criteria

Exclusion Criteria:

  1. Has evidence of hypovolemia or intravascular volume depletion (eg, hypotension, clinical evidence of volume depletion, response to saline challenge); if the subject has systolic blood pressure or heart rate outside of the normal range for that age volume status should be specifically clinically assessed to rule out volume depletion
  2. Has serum sodium \< 120 mmol/L, with or without associated neurologic impairment (ie, symptoms such as apathy, confusion, or seizures)
  3. Subjects ≤ 50 kg taking potent inhibitors or subjects \< 20 kg taking moderate CYP3A4 inhibitors within 72 hours prior to dosing
  4. Lacks free access to water (inability to respond to thirst) or without ICU-level fluid monitoring and management
  5. Has a history or current diagnosis of nephrotic syndrome
  6. Has transient hyponatremia likely to resolve (eg, head trauma or post-operative state)
  7. Has hyperkalemia defined as serum potassium above the for the appropriate pediatric age range
  8. Has \< 30 mL/min/1.73 m2 calculated by the following equation:

    eGFR (mL/min/1.73 m2) = 0.413 x height (cm)/serum creatinine (mg/dL)

  9. Has AKI from recent medical history defined as:

    • Increase in serum creatinine by ≥ 0.3 mg/dL (≥ 26.5 µmol/L) within 48 hours; or
    • Increase in serum creatinine to ≥ 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or
    • Urine volume \< 0.5 mL/kg/h for 6 hours
  10. Has severe or acute neurological symptoms requiring other intervention (eg, hyperemesis, obtundation, seizures)
  11. Has had treatment for hyponatremia with:

    • Hypertonic saline (including normal saline challenge) within 8 hours of qualifying serum sodium assessments;
    • Urea, lithium, demeclocycline, conivaptan, or tolvaptan within 4 days of qualifying serum sodium assessments;
    • Other treatment for the purpose of increasing serum sodium concurrent with dosing of IMP
  12. Has anuria or urinary outflow obstruction, unless the subject is, or can be, catheterized during the trial
  13. Has a history of drug or medication abuse within 3 months prior to Screening or current alcohol abuse
  14. Has a history of and/or idiosyncratic reaction to benzazepine or benzazepine derivatives (such as benazepril)
  15. Has psychogenic polydipsia (subjects with other psychiatric illness may be included per medical monitor approval)
  16. Has uncontrolled diabetes mellitus, defined as fasting glucose > 300 mg/dL (16.7 mmol/L)
  17. Has screening liver function values (/AST) > 3 x ULN
  18. Has cirrhosis and meets any of the following conditions: a major GI bleed within the past 6 months, evidence of active bleeding (eg, epistaxis, petechiae/purpura, hematuria, or hematochezia), count \< 50,000/µL, or use of concomitant medications known to increase bleeding risk
  19. Has hyponatremia due to the result of any medication that can safely be withdrawn (eg, thiazide diuretics)
  20. Has hyponatremia (eg, hyponatremia in the setting of adrenal insufficiency, untreated hypothyroidism, or hypotonic fluid administration) that is most appropriately corrected by alternative therapies
  21. Is currently pregnant or breastfeeding
  22. Has any medical condition that, in the opinion of the investigator, could interfere with evaluation of the trial objectives or safety of the subjects.
  23. Is deemed unsuitable for trial participation in the opinion of the investigator
  24. Participation in another drug trial within the past 30 days, without prior approval from the sponsor medical monitor
  25. Subjects \< 4 years of age or per local Health Authority age restriction, weight \< 10 kg, or who are unable to swallow tablets are excluded until an alternate formulation becomes available
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Tolvaptan

    Tolvaptan (3.75 mg, 7.5 mg, 15 mg, 30 mg, 60 mg dose daily depending on age and weight)

    Drug: Tolvaptan

  • Placebo comparator
    Placebo

    Placebo tablet matching active drug

    Other: Placebo

Interventions

  • Tolvaptan 3.75-, 7.5-, 15-, and 30-mg Tablets. Dosage: Depending on age, weight and serum sodium response: Tablet (3.75 mg - 60 mg daily) Frequency: Once daily Duration: 30 (+2) days

    Also known as: SAMSCA

  • OtherPlacebo

    Placebo tablet matching active drug

06

What researchers measure

Primary outcomes

  1. Change in serum sodium concentration

    The average daily area under the curve (AUC) of change from baseline in serum sodium level up to Day 4 within the double-blind treatment period.

    Time frame: Daily up to day 4

Secondary outcomes

  1. Change of average daily AUC from baseline at each visit in serum sodium level.

    Time frame: Daily up to Day 30

  2. Change from baseline in serum sodium concentration at Day 4.

    Time frame: Day 4

  3. Change from baseline in serum sodium concentration at Day 30.

    Time frame: Daily up to Day 30

  4. Percentage of subjects who require rescue therapy or fluid restriction at any time during the double-blind treatment period.

    Time frame: Daily up to Day 30

  5. Changes from baseline in ALT, AST and Total Bilirubin

    Time frame: Daily up to Day 30

  6. Clinically significant changes in vital signs.

    Time frame: Daily up to Day 30

  7. Incidence of dehydration AEs.

    Time frame: Daily up to Day 30

  8. Tanner staging progression score (at 30 days)

    Time frame: Daily up to Day 30

  9. Percentage of subjects with overly rapid correction in serum sodium ( ≥ 12 mmol/L in 24 hours).

    Time frame: Daily up to Day 30

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2015, a primary completion of Jun 2017 and a completion of Jun 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2015
First posted
May 13, 2015
Start
Nov 2015
Primary completionActual
Jun 22, 2017
CompletionActual
Jun 22, 2017
Last update
Jul 31, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02442674
Responsible party
Sponsor
First posted
May 13, 2015
Start date
Nov 2015
Primary completion
Jun 22, 2017
Completion
Jun 22, 2017
Last update
Jul 31, 2017

Study contacts

Ann Dandurand, MD
study director · Otsuka Pharmaceutical Development & Commercialization, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion